HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The brattleboro rat displays a natural deficit in social discrimination that is restored by clozapine and a neurotensin analog.

Abstract
Cognitive deficits in schizophrenia are a major source of dysfunction for which more effective treatments are needed. The vasopressin-deficient Brattleboro (BRAT) rat has been shown to have several natural schizophrenia-like deficits, including impairments in prepulse inhibition and memory. We investigated BRAT rats and their parental strain, Long-Evans (LE) rats, in a social discrimination paradigm, which is an ethologically relevant animal test of cognitive deficits of schizophrenia based upon the natural preference of animals to investigate conspecifics. We also investigated the effects of the atypical antipsychotic, clozapine, and the putative antipsychotic, PD149163, a brain-penetrating neurotensin-1 agonist, on social discrimination in these rats. Adult rats were administered saline or one of the three doses of clozapine (0.1, 1.0, or 10 mg/kg) or PD149163 (0.1, 0.3, or 1.0 mg/kg), subcutaneously. Following drug administration, adult rats were exposed to a juvenile rat for a 4-min learning period. Animals were then housed individually for 30 min and then simultaneously exposed to the juvenile presented previously and a new juvenile for 4 min. Saline-treated LE rats, but not BRAT rats, exhibited intact social discrimination as evidenced by greater time spent exploring the new juvenile. The highest dose of clozapine and the two highest doses of PD149163 restored social discrimination in BRAT rats. These results provide further support for the utility of the BRAT rat as a genetic animal model relevant to schizophrenia and drug discovery. The potential of neurotensin agonists as putative treatments for cognitive deficits of schizophrenia was also supported.
AuthorsD Feifel, S Mexal, Gilia Melendez, Philip Y T Liu, Joseph R Goldenberg, Paul D Shilling
JournalNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (Neuropsychopharmacology) Vol. 34 Issue 8 Pg. 2011-8 (Jul 2009) ISSN: 1740-634X [Electronic] England
PMID19322170 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Antipsychotic Agents
  • PD 149163
  • Receptors, Neurotensin
  • neurotensin type 1 receptor
  • Neurotensin
  • Clozapine
Topics
  • Animals
  • Antipsychotic Agents (pharmacology)
  • Brain (drug effects, metabolism, physiopathology)
  • Clozapine (pharmacology)
  • Cognition Disorders (drug therapy, etiology, physiopathology)
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Exploratory Behavior (drug effects, physiology)
  • Male
  • Mental Disorders (drug therapy, etiology, physiopathology)
  • Neurotensin (agonists, analogs & derivatives, metabolism, pharmacology)
  • Rats
  • Rats, Brattleboro
  • Rats, Long-Evans
  • Receptors, Neurotensin (agonists, metabolism)
  • Schizophrenia (complications, drug therapy, physiopathology)
  • Schizophrenic Psychology
  • Social Behavior

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: